$JBS

JBS Q2 Slips To Loss, Adj. EBITDA Drops; Stock Down

JBS N.V. reported a Q2 2026 net loss attributable to shareholders of $102.1 million, or $0.10 per share, versus net income of $528.1 million, or $0.48 per share a year earlier, despite higher net sales of $23.9 billion. Adjusted EBITDA fell 18.5% to $1.429 billion. JBS shares were down about 3% in NYSE overnight trading at $13.00.

Original reporting
Published Aug 11, 2026, 8:00 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 11, 2026, 8:28 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
JBS Q2 Slips To Loss, Adj. EBITDA Drops; Stock Down — source image
Decision brief

The 30-second read

$JBSBearishMed
01

Why it matters

The key tradable takeaway is deterioration in profitability metrics (net loss and lower adjusted EBITDA) alongside higher operating and finance expenses, which can drive multiple compression and earnings revisions.

02

Market read

JBS’s Q2 profitability miss (loss and lower adjusted EBITDA) is likely to dominate the stock reaction, even with revenue growth.

03

What to watch

Finance expense rose sharply ($831.2M vs $445.8M), so traders may separate operating performance from capital structure and interest-rate/refinancing effects.

Relevance 7/10Novelty 6/10Timing: pre-market today (overnight NYSE trading down ~3%)

Background

The article summarizes JBS’s Q2 2026 results versus the prior year, highlighting net loss, adjusted EBITDA decline, and expense increases.

Company-level read

Ticker impact

$JBSBearishMedium confidence
Context

JBS reported a Q2 2026 net loss of $102.1M and an 18.5% decline in adjusted EBITDA despite higher net sales.

Expected impact

Bearish bias for the next few sessions, with follow-through risk if investors focus on margin/expense and finance cost increases.

Evidence & confidence

The article provides directionally clear deterioration: net loss vs prior-year profit, adjusted EBITDA down 18.5%, operating expenses and finance expense both higher, even as sales rose.

Market effects

Packaged food peers may see read-across on cost inflation and financing expense sensitivity, though this is company-specific.

Limited direct regional spillover indicated; focus remains on company fundamentals.

No explicit global macro or cross-border transaction details beyond the company’s reported results.

Counterpoint

Higher net sales alongside a smaller adjusted EBITDA decline could imply demand resilience, with the loss driven by non-operating items rather than core volume weakness.

Key entities

  • JBS N.V.

    Packaged food products provider reporting Q2 2026 net loss and lower adjusted EBITDA despite higher sales.

Related articles

$JBSMedAI 8/10

JBS N.V. (JBS): Results of Operations and Financial Condition

JBS N.V. (JBS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ea030137401ex99-1.htm EARNINGS RELEASE ANNOUNCING JBS N.V.'S RESULTS FOR THE QUARTER ENDED JUNE 30, 2026 Exhibit 99.1 JBS REPORTS SECOND QUARTER 2026 RESULTS August 10, 2026 – JBS N.V. (NYSE: JBS; B3: JBSS32), announces today its 2Q26 results. The numbers reported herei

$JBSMed

Why is JBS stock sliding today?

JBS NV shares fell 5.7% to $13.43 as investors weighed earnings risk ahead of its Q2 2026 results after the close. Analysts expect EPS of about $0.33 on revenue near $22.77B, implying roughly a 40% year-over-year profitability drop. The stock also reacted to a leadership change: Wesley Batista Filho to become Global CEO in Jan 2027.

$JBSMedAI 8/10

Danantara takes stake in JBS Australia and NZ operations

Danantara Investment Management will buy a 25% stake in JBS’s Australia and New Zealand operations, investing USD 2.5 billion (AUD 3.5 billion). The partnership may add up to USD 2.5 billion more capacity, targeting acquisitions and greenfield growth across Indonesia, Australia, New Zealand and Southeast Asia. Deal is subject to Australian regulatory approvals.

$JBSMedAI 9/10

JBS Signs Deal Worth Up to US$5 Billion in Indonesia

JBS SA (NYSE: JBS) said it signed a binding agreement with PT Danantara Investment Management, an arm of Indonesia’s sovereign wealth fund, to form an Asia-Pacific protein joint venture worth up to US$5 billion. Danantara will inject US$2.5 billion equity for a 25% stake in two phases, with JBS contributing its Australia and New Zealand operations. The venture may later raise up to US$2.5 billion debt, subject to approvals.

$JBSMedAI 8/10

JBS targets Southeast Asia growth with $2.5 billion deal

JBS said it will expand in Indonesia, Australia and New Zealand via a partnership with Danantara Investment Management. Danantara will invest $2.5 billion for a 25% equity stake in JBS’s Australia and New Zealand operations, subject to Australian regulatory approvals. JBS expects up to $5 billion total capital for future growth.